Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteolysis of mature HIV-1 p6 Gag protein by the insulin-degrading enzyme (IDE) regulates virus replication in an Env-dependent manner.
Hahn F, Schmalen A, Setz C, Friedrich M, Schlößer S, Kölle J, Spranger R, Rauch P, Fraedrich K, Reif T, Karius-Fischer J, Balasubramanyam A, Henklein P, Fossen T, Schubert U. Hahn F, et al. Among authors: spranger r. PLoS One. 2017 Apr 7;12(4):e0174254. doi: 10.1371/journal.pone.0174254. eCollection 2017. PLoS One. 2017. PMID: 28388673 Free PMC article. Clinical Trial.
[Safety monitoring of cell-based medicinal products (CBMPs)].
Funk MB, Frech M, Spranger R, Keller-Stanislawski B. Funk MB, et al. Among authors: spranger r. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1239-46. doi: 10.1007/s00103-015-2240-4. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015. PMID: 26391098 Review. German.
Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.
Watada H, Takami A, Spranger R, Amano A, Hashimoto Y, Niemoeller E. Watada H, et al. Among authors: spranger r. Diabetes Care. 2020 Jun;43(6):1249-1257. doi: 10.2337/dc19-2452. Epub 2020 Apr 15. Diabetes Care. 2020. PMID: 32295808 Free PMC article. Clinical Trial.
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
Terauchi Y, Nakama T, Spranger R, Amano A, Inoue T, Niemoeller E. Terauchi Y, et al. Among authors: spranger r. Diabetes Obes Metab. 2020 Sep;22 Suppl 4:14-23. doi: 10.1111/dom.14036. Diabetes Obes Metab. 2020. PMID: 32291880 Clinical Trial.
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
Kaneto H, Takami A, Spranger R, Amano A, Watanabe D, Niemoeller E. Kaneto H, et al. Among authors: spranger r. Diabetes Obes Metab. 2020 Sep;22 Suppl 4:3-13. doi: 10.1111/dom.14005. Diabetes Obes Metab. 2020. PMID: 32072742 Clinical Trial.
26 results